Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using ...

Kathy Davis of Canonsburg underwent heart surgery, but complications left her with right heart failure, a condition where the ...

Some workers are willing to trade vacation days or go back to the office in exchange for weight-loss drug coverage by their ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really ...

The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline. Click for my LLY stock update.

Ozempic rose 12%, while Wegovy rose 107% at ... Estimate of $1.35 billion and our model estimate of $1.45 billion. Jardiance sales rose 50% to $1.2 billion, including the one-time payment received ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease (CKD), according to Spherix Global Insights.